WT1 126-134 peptide acetate is a Wilms' tumor oncogene protein ( WT1 ) peptide (RMFPNAPYL). WT1 126-134 peptide acetate is presented by HLA-A0201 and induces cytotoxic CD8 T cells capable of killing WT1+ positive tumor cells. WT1 126-134 can form stable complexes with the H-2Db (mouse) or HLA-A0201 (human) molecules. WT1 126-134 peptide acetate/HLA-A0201 complex has an extremely high affinity ( K d = 0.2 nM) with the humanized monoclonal antibody ( IgG1 ). WT1 126-134 peptide acetate can be used as a vaccine for T cells or as a target for antibodies [1] [2] [3].
In Vivo, WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 2 weeks) acetate induces epitope-specific CTL, but fails to produce a significant anti-tumor effect in the TRAMP-C2 model[1]. WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 3 weeks) acetate combined with the auxiliary peptide (WT135-52) significantly enhances CTL induction and delays tumor growth induced by mWT1-C1498 cells in mice[3].
References:
[1]. Shirakawa T, Kitagawa K. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. Hum Vaccin Immunother. 2018 Jan 2;14(1):159-162.
[2]. David A, et al, A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes. Blood 2011; 118 (21): 1677.
[3]. Nakajima H, et al. Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunol Immunother. 2021 Nov;70(11):3323-3335.
In Vivo, WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 2 weeks) acetate induces epitope-specific CTL, but fails to produce a significant anti-tumor effect in the TRAMP-C2 model[1]. WT1 126-134 peptide (100 μg, emulsified with incomplete Freund’s adjuvant, i.p., once a week for 3 weeks) acetate combined with the auxiliary peptide (WT135-52) significantly enhances CTL induction and delays tumor growth induced by mWT1-C1498 cells in mice[3].
References:
[1]. Shirakawa T, Kitagawa K. Antitumor effect of oral cancer vaccine with Bifidobacterium delivering WT1 protein to gut immune system is superior to WT1 peptide vaccine. Hum Vaccin Immunother. 2018 Jan 2;14(1):159-162.
[2]. David A, et al, A Cytotoxic Human Monoclonal Antibody Recognizing Cell Surface WT1 Peptide/HLA-A2 Complexes. Blood 2011; 118 (21): 1677.
[3]. Nakajima H, et al. Identification of mouse helper epitopes for WT1-specific CD4+ T cells. Cancer Immunol Immunother. 2021 Nov;70(11):3323-3335.